NORBERTO TUASON: Open Payments
NPI 1841338555 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,993 in 66 payments from 12 companies in 2025. Trend: 2023 $3,143 · 2024 $595 · 2025 $1,993
Food & beverage: $1,993
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 14 | $483 |
| Supernus Pharmaceuticals, Inc. | 23 | $262 |
| ABBVIE INC. | 2 | $247 |
| E.R. Squibb & Sons, L.L.C. | 9 | $237 |
| Otsuka America Pharmaceutical, Inc. | 6 | $232 |
| Alkermes, Inc. | 5 | $182 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| Biogen, Inc. | 1 | $121 |
| Janssen Pharmaceuticals, Inc | 2 | $55 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
Products named: FANAPT, Qelbree, VRAYLAR, COBENFY, REXULTI, ARISTADA, Auvelity, ZURZUVAE.
Industry payments across CA — which companies pay providers there.
